Lyra Therapeutics (LYRA) Projected to Post Quarterly Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) is expected to be announcing its Q1 2026 resultson Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Lyra Therapeutics Price Performance

Shares of NASDAQ LYRA traded down $0.02 during trading hours on Tuesday, reaching $0.73. The stock had a trading volume of 272 shares, compared to its average volume of 76,120. The business’s fifty day moving average is $0.82 and its two-hundred day moving average is $2.59. The company has a market cap of $1.30 million, a price-to-earnings ratio of -0.03 and a beta of 0.68. Lyra Therapeutics has a twelve month low of $0.31 and a twelve month high of $37.50.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Lyra Therapeutics by 33.7% during the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after acquiring an additional 7,190 shares in the last quarter. DRW Securities LLC acquired a new position in Lyra Therapeutics during the fourth quarter worth $52,000. Finally, Citadel Advisors LLC acquired a new position in Lyra Therapeutics during the third quarter worth $128,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lyra Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).